U
Ulrich Speck
Researcher at Charité
Publications - 74
Citations - 4249
Ulrich Speck is an academic researcher from Charité. The author has contributed to research in topics: Restenosis & Angioplasty. The author has an hindex of 20, co-authored 72 publications receiving 3943 citations. Previous affiliations of Ulrich Speck include Schering AG.
Papers
More filters
Journal ArticleDOI
Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg.
Gunnar Tepe,Thomas Zeller,Thomas Albrecht,S. Heller,Uwe Schwarzwälder,Jean-Paul Beregi,M.D. Claus D. Claussen,A. Oldenburg,Bruno Scheller,Ulrich Speck +9 more
TL;DR: Use of paclitaxel-coated angioplasty balloons during percutaneous treatment of femoropopliteal disease is associated with significant reductions in late lumen loss and target-lesion revascularization and no significant benefit is seen with the use of a paclitxel-containing contrast medium.
Journal ArticleDOI
Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.
Bruno Scheller,Christoph Hehrlein,Wolfgang Bocksch,Wolfgang Rutsch,Dariush Haghi,Ulrich Dietz,Michael Böhm,Ulrich Speck +7 more
TL;DR: A randomized, double-blind, multicenter trial to compare the effects of a balloon catheter coated with paclitaxel (3 μg per square millimeter of balloon surface area) with those of an uncoated balloons catheter in coronary angioplasty found no significant differences.
Journal ArticleDOI
Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial.
Michael Werk,Soenke Langner,Bianka Reinkensmeier,Hans-Frank Boettcher,Gunnar Tepe,Ulrich Dietz,Norbert Hosten,Bernd Hamm,Ulrich Speck,Jens Ricke +9 more
TL;DR: Paclitaxel balloon coating caused no obvious adverse events and reduced restenosis in patients undergoing angioplasty of femoropopliteal arteries and the difference in target lesion revascularizations between treatment groups was maintained up to >18 months.
Journal ArticleDOI
Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis.
TL;DR: Paclitaxel balloon coating is safe, and it effectively inhibits restenosis after coronary angioplasty with stent implantation in the porcine model, and the degree of reduction in neointimal formation was comparable to that achieved with drug-eluting stents.
Journal ArticleDOI
Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter
Bruno Scheller,Christoph Hehrlein,Wolfgang Bocksch,Wolfgang Rutsch,Dariush Haghi,Ulrich Dietz,Michael Böhm,Ulrich Speck +7 more
TL;DR: Treatment of coronary ISR with paclitaxel-coated balloon catheters persistently reduces repeat restenosis up to 2 years and after a complete follow-up of 2 years.